Please find attached press release dated August 20, 2026.

August 20, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Press Release Please find enclosed herewith the Press Release titled “Mankind Pharma Enters into Exclusive In- Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India”, which is self-explanatory and same has been released to the press today. The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com. You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combina(cid:415)on for India Partnership further strengthens Mankind Pharma’s growing presence in the diabetes segment and expands its injectable diabetes por(cid:414)olio New Delhi, 20th August 2026 : Mankind Pharma Limited, one of India’s leading pharmaceu(cid:415)cal companies, has entered into an exclusive in-licensing and marke(cid:415)ng agreement with Chongqing Chenan Biopharmaceu(cid:415)cal Co., Ltd., China, for the commercialisa(cid:415)on of two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combina(cid:415)on, in India. The partnership marks another significant step in Mankind Pharma’s strategy to strengthen its presence in diabetes care and broaden its por(cid:414)olio of advanced injectable therapies. The addi(cid:415)on of these products will further enhance, Mankind Pharma’s posi(cid:415)on in the injectable diabetes segment, contribu(cid:415)ng to a more comprehensive por(cid:414)olio and reinforcing its commitment to addressing the evolving needs of pa(cid:415)ents. The latest partnership further reinforces the company’s commitment to expanding its diabetes por(cid:414)olio and bringing a broader range of treatment op(cid:415)ons to pa(cid:415)ents in India. Commen(cid:415)ng on the partnership, A(cid:415)sh Majumdar, Senior President – Sales and Marke(cid:415)ng, Mankind Pharma Ltd., said, “China is rapidly emerging as a hub for innova(cid:415)ve biopharmaceu(cid:415)cal assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China. This partnership reinforces our commitment to expanding access to advanced therapies for pa(cid:415)ents in India while further strengthening our presence in the injectable diabetes segment.” The partnership with Chongqing Chenan Biopharmaceu(cid:415)cal is also aligned with Mankind Pharma’s broader strategy of leveraging global innova(cid:415)on through strategic partnerships and in-licensing opportuni(cid:415)es. China’s rapidly developing biopharmaceu(cid:415)cal ecosystem presents opportuni(cid:415)es for Indian pharmaceu(cid:415)cal companies to access differen(cid:415)ated and innova(cid:415)ve assets that can complement their exis(cid:415)ng por(cid:414)olios. About Mankind Pharma Limited Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceu(cid:415)cal company in India, which focuses on the domes(cid:415)c market with its Pan India presence. Mankind operates at the intersec(cid:415)on of the Indian pharmaceu(cid:415)cal formula(cid:415)ons and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domes(cid:415)c pharmaceu(cid:415)cals business present across acute and chronic therapeu(cid:415)c areas including an(cid:415)-infec(cid:415)ves, cardiovascular, gastrointes(cid:415)nal, an(cid:415)diabe(cid:415)c, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detec(cid:415)on, emergency contracep(cid:415)ves, antacid powders, vitamin and mineral supplements and an(cid:415)-acne prepara(cid:415)ons categories, among others, with several category-leading brands. Following the acquisi(cid:415)on of BSV, Mankind Pharma has further strengthened its leadership in the domes(cid:415)c women’s health segment. Mankind's distribu(cid:415)on network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facili(cid:415)es in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, so(cid:332) and hard gels, eye drops, creams, contracep(cid:415)ves and other over-the-counter products. Mankind has a consistent track record of product innova(cid:415)on through 7 dedicated R&D facili(cid:415)es backed by more than 740 scien(cid:415)sts. For more informa(cid:415)on, visit www.mankindpharma.com or contact: Natasha Raj - 9205057627 - natasha.raj@mankindpharma.com Apoorva Sharma - 9999739452 - apoorva.sharma@adfactorspr.com